{"id":"W4401433011","doi":"10.1016/j.clml.2024.07.014","title":"Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Vancouver General Hospital; Surrey Place Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"EMD Serono; Pharmacyclics; Genentech; Incyte; bluebird bio; Celgene; Teva Pharmaceutical Industries; Gilead Sciences; BeiGene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Pomalidomide; Lenalidomide; Medicine; Daratumumab; Internal medicine; Dexamethasone; Multiple myeloma; Cohort; Clinical endpoint; Adverse effect; Oncology; Refractory (planetary science); Discontinuation; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008849609,0.0003997771,0.0004760807,0.0003670771,0.0003422403,0.0005697572,0.0003484385,0.0003034541,0.001324006],"category_scores_gemma":[0.0007063749,0.0001357189,0.000531924,0.0002854151,0.0001818738,0.0003247422,0.0005249147,0.0007972064,0.0002623214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005483046,"about_ca_system_score_gemma":0.0005176116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001269851,"about_ca_topic_score_gemma":0.001547205,"domain_scores_codex":[0.9997661,0.00005314083,0.0000217033,0.00005515038,0.00004851821,0.00005540695],"domain_scores_gemma":[0.9995222,0.00006751826,0.0001423061,0.00003990174,0.00003749008,0.0001905664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05513704,0.001648113,0.8233452,0.0001779679,0.001006844,0.001035463,0.0002981991,0.001594704,0.01198919,0.00010063,0.003919243,0.0997474],"study_design_scores_gemma":[0.003914737,0.02390185,0.9587122,0.00007370453,0.0008837314,0.002300649,0.0002208267,0.001732457,0.002773719,0.0002411048,0.005212882,0.00003212],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979646,0.0005637418,0.00009082298,0.00005994623,0.000008636493,0.00002721682,0.000759106,0.00001029305,0.0005156117],"genre_scores_gemma":[0.9975842,0.0002469991,0.0001003993,0.00006368872,0.00002054518,0.00002358742,0.00168175,0.000003235309,0.0002755923],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001324006,"threshold_uncertainty_score":0.004680216,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0919602946311303,"score_gpt":0.3804131323060837,"score_spread":0.2884528376749534,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}